A study to evaluate the relative bioavailability and effect of food on MK-3682B Fixed-Dose Combination Tablet (MK-3682/MK-8408/MK-5172) - MK3682-016

QPS Netherlands B.V.0 个研究点目标入组 22 人开始时间: 待定最近更新: 2024年4月23日

适应症

试验速览

暂无简介。

•1. Willing to give written informed consent, including for Future Biomedical Research.
•2. Male or female 18 to 45 years of age (inclusive) at the pretrial (screening) visit.
•3. Standard liver function tests including ALT, AST, alkaline phosphatase and total bilirubin do not exceed the upper limit of normal for the local laboratory at screening and on Day -1 of Period 1. If total bilirubin is elevated, direct bilirubin will be measured and the subject may be eligible for inclusion if direct bilirubin is within normal limits.

•1. A history of liver disease (exception: subjects with remote hepatitis A virus infection with full recovery can be included).
•2. Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV).
•3. A history of cancer (malignancy).

发起方

QPS Netherlands B.V.